5 papers and 0 clinical trials exploring lsd as a treatment for neurological injury.
LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.
Full LSD profileNeurological injury encompasses various forms of brain damage resulting from trauma, strokes, or other factors, leading to significant functional impairment. Recent research into psychedelic compounds presents promising avenues for innovative therapeutic interventions aimed at enhancing recovery and alleviating associated psychological conditions such as PTSD and depression.
Full Neurological Injury profileNo clinical trials have been tagged with both LSD and Neurological Injury yet.
Trials are continuously being added as new studies are registered.